A phase I/II study of sepantronium bromide (YM155, survivin suppressor) with paclitaxel and carboplatin in patients with advanced non-small-cell lung cancer

BACKGROUND: This phase I/II study examined the safety and efficacy of Sepantronium Bromide (S), a small-molecule selective survivin suppressant, administered in combination with carboplatin (C) and paclitaxel (P). PATIENTS AND METHODS: Forty-one patients were treated on study. Twenty-two patients re...

Description complète

Enregistré dans:
Détails bibliographiques
Auteurs principaux: Kelly, R. J., Thomas, A., Rajan, A., Chun, G., Lopez-Chavez, A., Szabo, E., Spencer, S., Carter, C. A., Guha, U., Khozin, S., Poondru, S., Van Sant, C., Keating, A., Steinberg, S. M., Figg, W., Giaccone, G.
Format: Artigo
Langue:Inglês
Publié: Oxford University Press 2013
Sujets:
Original Articles
Accès en ligne:https://ncbi.nlm.nih.gov/pmc/articles/PMC3784336/
https://ncbi.nlm.nih.gov/pubmed/23857959
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/annonc/mdt249
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires